Covid19, VaccinesNCT04801524
Text-based Reminders to Promote COVID-19 Vaccinations
A study testing Self-benefit, Prosocial-benefit and Early access in people with Covid19, Vaccines, run by University of California, Los Angeles at 1 site in United States.
Trial summary
This study investigates whether and which type of text-based reminders affect the take-up of the COVID-19 vaccine. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Covid19, Vaccines
- What is being tested?
- Self-benefit, Prosocial-benefit and Early access
- Type of treatment
- Vaccines, Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 250,000 participants
- Where
- 1 siteUnited States
- Study dates
- 7 Feb 2021to 1 Jan 2022
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- All patients who satisfy the following criteria will be eligible to be included in our study:
- They have a mobile phone number or SMS capable phone number in UCLA Health's database
- They are eligible for receiving the COVID-19 vaccine at UCLA Health
- They have not already scheduled an appointment the day before the scheduled time of the text message
- They are at or above 18 years old
- Exclusion Criteria: Patients who already scheduled an appointment or obtained a COVID vaccine (at our collaborating health system or as documented in the California Immunization Registry (CAIR) https://cairweb.org) by the time our text message is sent will be excluded from the analysis.
Who cannot join
None listed.
Trial locations and contacts
1 site in 1 country.
United States1 site
UCLA Health Department of Medicine, Quality Office
Westwood, Los Angeles, California, 90095
About this study
This study investigates whether and which type of text-based reminders affect the take-up of the COVID-19 vaccine.
Read the detailed description
Our primary research question is whether vaccine takeup can be boosted by a text-message reminder encouraging eligible patients to schedule a vaccination appointment. Patients, when becoming eligible for receiving the COVID-19 vaccine at UCLA Health, will be first notified about their eligibility and encouraged to schedule a vaccination appointment via one of the channels (email, voice call, or snail mail) depending on the contact information available to UCLA Health. Eligible patients will also receive a text-message reminder after the initial invitation. Eight days after the first text reminder, patients eligible for our study will be randomized at a 1:6 ratio into a holdout control arm that does not receive a second text message vs. a text-message arm that receives a second text message.
Our secondary research question concerns which type of text reminder is more effective. To study this question, we will nest a 2x3 factorial design within the text-message arm. The first factor has two levels and is whether the text message focuses on patients' personal benefits or prosocial benefits. The second factor has three levels and is whether the text message highlights the early access patients have to the vaccine, whether it highlights that the vaccine offers the promise of a fresh start, or neither.
- In the Holdout arm: patients will not receive a second text message about COVID-vaccine.
- In the text-message arm, all participants will receive a text message that invites them to schedule their vaccination appointment and includes a link to the appointment website
- In the Self-benefit sub-arm, participants will be reminded that the vaccine helps protect themselves from COVID.
- In the Prosocial-benefit sub-arm, participants will be reminded that the vaccine helps protect their family, friends, and community from COVID.
- In the Early access + self-benefit sub-arm, participants will be reminded that they have early access to COVID-19 vaccine and should take the opportunity to protect themselves from COVID.
- In the Early access + prosocial-benefit sub-arm, participants will be reminded that they have early access to COVID-19 vaccine and should take the opportunity to protect their family, friends, community from COVID.
- In the Fresh start + self-benefit sub-arm, participants will be reminded that the vaccine offers the promise of a fresh start and they should take the opportunity to protect themselves from COVID and chart a new path forward.
- In the Early access + prosocial-benefit sub-arm, participants will be reminded that the vaccine offers the promise of a fresh start and they should take the opportunity to protect their family, friends, community from COVID and help our nation chart a new path forward.
Patients will enter our study on a rolling basis, as they become eligible to get the vaccine (and if they fit our inclusion criteria for receiving the second text message). Those in the text-message arm will receive the second text message on the workday on or closest to the 8th day following the first text message. Specifically, if t denotes the date of the first text message, then t+8 is the 8th day following the first text message.If t+8 is Saturday, the second text message will be sent on Friday; if t+8 is Sunday, the second text message will be sent on Monday. We will measure a) whether patients schedule a COVID-19 vaccination appointment for the first dose and b) whether and when patients get the first dose of COVID-19 vaccine.
The study will stop assigning patients to the early access + self-benefit sub-arm OR the early access + prosocial-benefit sub-arm when UCLA health opens appointments to everyone regardless of priority status related to age, health conditions or occupations. This will be done because at this point the concept of early access is likely no longer credible. At that point, we will randomize future patients eligible for our study at a 1:4 ratio into the holdout control arm and a text-message arm that receives a second text message. Within the text-message arm, we will nest a 2x2 factorial design, where the two factors will be a) whether the text message will focus on patients' personal benefits or prosocial benefits and b) whether or not the text message highlights that the vaccine offers the promise of a fresh start.
Analysis:
For the main analysis, we will run ordinary least squares regressions (OLS) with robust standard errors to predict the aforementioned outcome variables, except that we will use a Cox proportional hazards model with administrative censoring to predict time of obtaining the first COVID-19 vaccine. The significance level will be 0.05. Our primary hypothesis is that the text-message arm is significantly better than the holdout arm, so our primary analysis will compare the six text-message sub-arms altogether with the holdout group.
Our secondary analysis will investigate whether (1) the three sub-arms highlighting self-benefits, (2) the three sub-arms highlighting prosocial benefits, (3) the two sub-arms highlighting early access, and (4) the two sub-arms highlighting fresh start are better than the holdout arm.
Furthermore, we will test (1) the effect of highlighting prosocial benefits (vs. self-benefits), (2) the effect of highlighting early access, (3) the effect of highlighting the promise of a fresh start, (4) whether the combination of early access and prosocial benefits will outperform early access alone or prosocial benefits alone, and (5) whether the combination of fresh start and prosocial benefits will outperform fresh start alone or prosocial benefits alone.
Our regressions will include the following control variables:
- Participant age
- Indicators for participant race/ethnicity (Black non-Hispanic, Hispanic, Asian non-Hispanic, white non-Hispanic, other/mixed, unknown; white non-Hispanic omitted)
- Whether the patient's preferred language is Spanish (which affects the language of text)
- Indicators for participant gender (male, female, other/unknown)
- Social vulnerability index score
- COVID19 Risk Factors Model
- Indicators for the batches of patients (patients will become eligible and receive initial communications in batches)
As a robustness check, we will re-run the analysis as a logit regression (instead of an OLS regression) for binary outcome variables.
We will explore the following moderators:
- Whether the patient is female or male
- Whether the patient is Black, Caucasian, Hispanic, or other
- Whether the patient's preferred language is Spanish
- Whether the patient is 65+ (including 65) or below 65
- Patient's Social vulnerability index score
- Patient's COVID risk score
- Patient's population risk score
- Whether the patient is married (which is a proxy for whether they live together with family members)
- Whether or not the patient received a flu shot in either the 2019-2020 season or the 2020-2021 flu season prior to receiving our text message according to the patient's medical record
- The day of the week when the text message is sent to a patient. We will compare each day of the week.
- How strongly the participant's neighborhood is in favor of the Republican (vs. Democratic) Party if UCLA Health eventually agrees to provide de-identified address (e.g., zipcode)
- The arm that patients were assigned to for the first text message (see our pre-registration for the RCT related to the first text message at NCT04800965)
- Number of days between the date the first batch of patients received the initial invitation to get COVID vaccine at UCLA Health and the date a patient in question received the initial invitation
- The number of patients who have received the initial invitation to get COVID vaccine at UCLA Health before a patient in question received the initial invitation.
Plan for Early and Subsequent Analyses
To inform policy as soon as possible, we plan to first assess the effects of our interventions in the early phase of vaccination outreach at UCLA Health. For this purpose, we plan to first analyze the data from the start of this RCT to the end of February. Given that we are using a 6-day time window for our primary dependent variable, we will examine data from patients who are randomized to either the holdout or text-message arm in this RCT before or on Feb 23, 2021. For this population, we will test:
- whether the text-message arm is significantly better than the holdout arm;
- whether the three sub-arms highlighting self-benefits, the three sub-arms highlighting prosocial benefits, the two sub-arms highlighting early access, and the two sub-arms highlighting fresh start are better than the holdout arm.
- we will report the raw data for each sub-arm without conducting hypothesis testing across conditions that are not pre-registered in (1)-(4).
In our early analysis, we will include controls that are available to us (it is possible that we do not have all of the controls described above at the time of early report).
However, if by Feb 23, we do not reach 40K (which gives us 80% power to detect a 2pp difference between the holdout arm and the text message arm, assuming that holdout arm has a 50% baseline) for this RCT, we will only report estimated treatment effects and 95% confidence intervals but we will not perform any hypothesis testing.
After all UCLA patients have been invited (or if vaccine distribution plan changes and UCLA Health no longer sends out text messages to patients at some point), we will do the following additional analyses:
- If the additional data collected afterward exceeds 40K (which gives us 80% power to detect a 2pp difference between the holdout arm and the text message arm), then we will analyze the main effect of sending a text message (vs. holdout) and report the raw data for each sub-arm (to see if the patterns are qualitatively comparable with those in the early data).
- If we do not reach the sample size for the early analysis, then we will use all the data (including the early data and subsequent data) to analyze the aforementioned questions for the early data.
- We will use the full sample (including the early data and subsequent data) to analyze (1) the effect of highlighting prosocial benefits (vs. self-benefits), (2) the effect of highlighting early access, (3) the effect of highlighting the promise of a fresh start, (4) whether the combination of early access and prosocial benefits will outperform early access alone or prosocial benefits alone, and (5) whether the combination of fresh start and prosocial benefits will outperform fresh start alone or prosocial benefits alone, and (6) the aforementioned heterogeneous treatment effects.
- Conditions
- Covid19, Vaccines
- Being tested
- Self-benefit, Prosocial-benefit, Early access, Fresh start
- Keywords
- COVID19, Vaccines, Text-messages, Patient Outreach, Behavioral Science
- Medical subject headings
- COVID-19
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Self-benefitBehavioural
Participants will be reminded that the vaccine helps protect themselves from COVID.
Prosocial-benefitBehavioural
Participants will be reminded that the vaccine helps protect their family, friends, and community from COVID
Early accessBehavioural
Participants will be reminded that they have early access to COVID-19 vaccine.
Fresh startBehavioural
Participants will be reminded that the vaccine offers the promise of a fresh start and chart a new path forward.
| Study group | Role | What they receive |
|---|---|---|
| Holdout Arm | No intervention | In the Holdout arm: patients will not receive a second text message about COVID-vaccine. |
| Self-benefit sub-arm | Experimental | In the Self-benefit sub-arm, participants will be reminded that the vaccine helps protect themselves from COVID. Receives: Behavioral: Self-benefit |
| Prosocial-benefit sub-arm | Experimental | In the Prosocial-benefit sub-arm, participants will be reminded that the vaccine helps protect their family, friends, and community from COVID. Receives: Behavioral: Prosocial-benefit |
| Early-access and self-benefit sub-arm | Experimental | In the Early access + self-benefit sub-arm, participants will be reminded that they have early access to COVID-19 vaccine and should take the opportunity to protect themselves from COVID. Receives: Behavioral: Self-benefit; Behavioral: Early access |
| Early-access and prosocial-benefit sub-arm | Experimental | In the Early access + prosocial-benefit sub-arm, participants will be reminded that they have early access to COVID-19 vaccine and should take the opportunity to protect their family, friends, community from COVID. Receives: Behavioral: Prosocial-benefit; Behavioral: Early access |
| Fresh start and self-benefit sub-arm | Experimental | In the Fresh start + self-benefit sub-arm, participants will be reminded that the vaccine offers the promise of a fresh start and they should take the opportunity to protect themselves from COVID and chart a new path forward. Receives: Behavioral: Self-benefit; Behavioral: Fresh start |
| Fresh start and prosocial-benefit sub-arm | Experimental | In the Early access + prosocial-benefit sub-arm, participants will be reminded that the vaccine offers the promise of a fresh start and they should take the opportunity to protect their family, friends, community from COVID and help our nation chart a new path forward. Receives: Behavioral: Prosocial-benefit; Behavioral: Fresh start |
What is being measured
The primary outcome is the main question the study is designed to answer.
First COVID-19 Vaccine Appointment Scheduled at UCLA Health
Whether patients schedule their vaccination appointment at UCLA Health within 6 days of receiving the second text message (including the day of text message). Specifically, if t=the date of the second text message (for the holdout arm, this refers to the date they would have received the text message had they not been assigned to the holdout arm), we will track vaccination appointments made by the end of t+5. While most people just make one appointment, a small percentage update their appointment time. We will have access to the latest few first-dose appointments people schedule by the time of data extraction.
Measured: 6 days
Secondary outcomes (4)
First COVID-19 Vaccine obtained at UCLA Health
Whether patients get the first dose of COVID-19 vaccine at UCLA Health [time frame: 1 months from text message]
Measured: 1 months from text message
Time of obtaining the first COVID-19 vaccine at UCLA Health
The date when patients obtain the first dose of COVID-19 vaccine at UCLA Health [time frame: 1 months from text message]
Measured: 1 months from text message
First COVID-19 Vaccine obtained at UCLA Health or any organization reporting to CAIR
Whether patients obtain the first dose of COVID-19 vaccine at UCLA Health or another location reporting to the California Immunization Registry (CAIR). [time frame: 2 months from text message]
Measured: 2 months from text message
Time of obtaining the first COVID-19 at UCLA Health or another location reporting to CAIR
The date when patients obtain the first dose of COVID-19 vaccine at UCLA Health or another location reporting to the California Immunization Registry (CAIR) [time frame: 2 months from text message]
Measured: 2 months from text message
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Mar 2021
- Study start7 Feb 2021
- Primary completion31 Dec 2021
- Study completion1 Jan 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (3)Papers the sponsor has linked to this study.
- Other trials for Covid19, VaccinesStudies of the same condition, open and under way.
- More trials run by University of California, Los AngelesThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Health services research
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Care provider
- Enrolment
- 250,000 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of California, Los Angeles
- Sponsor type
- University, hospital or other
- Collaborators
- Carnegie Mellon University
- Responsible party
- Principal investigator, Daniel M. Croymans, MD, MBA, MS, University of California, Los Angeles
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04801524
- Sponsor's protocol ID
- IRB#21-000268 (2)
- Status last verified
- Sep 2022
- First submitted
- 15 Mar 2021
- Last updated
- 13 Sep 2022
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Brewer NT, Chapman GB, Rothman AJ, Leask J, Kempe A. Increasing Vaccination: Putting Psychological Science Into Action. Psychol Sci Public Interest. 2017 Dec;18(3):149-207. doi: 10.1177/1529100618760521.
PubMed 29611455Volpp KG, Loewenstein G, Buttenheim AM. Behaviorally Informed Strategies for a National COVID-19 Vaccine Promotion Program. JAMA. 2021 Jan 12;325(2):125-126. doi: 10.1001/jama.2020.24036. No abstract available.
PubMed 33315079Dai, H., Milkman, K. L., & Riis, J. (2014). The fresh start effect: Temporal landmarks motivate aspirational behavior. Management Science, 60(10), 2563-2582.
Study at a glance
From the registry record, last updated by the sponsor on 13 Sep 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Text-based Reminders to Promote COVID-19 Vaccinations
- ClinicalTrials.gov ID
- NCT04801524
- Acronym / sponsor ID
- IRB#21-000268 (2)
- Conditions
- Covid19, Vaccines
- Keywords
- COVID19, Vaccines, Text-messages, Patient Outreach, Behavioral Science
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 250,000 participants (actual)
- Lead sponsor
- University of California, Los AngelesUniversity, hospital or other
- Collaborators
- Carnegie Mellon University
- Study start
- 7 Feb 2021 (actual)
- Primary completion
- 31 Dec 2021 (actual)
- Study completion
- 1 Jan 2022 (actual)
- First posted
- 17 Mar 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study investigates whether and which type of text-based reminders affect the take-up of the COVID-19 vaccine.
Detailed description
Our primary research question is whether vaccine takeup can be boosted by a text-message reminder encouraging eligible patients to schedule a vaccination appointment. Patients, when becoming eligible for receiving the COVID-19 vaccine at UCLA Health, will be first notified about their eligibility and encouraged to schedule a vaccination appointment via one of the channels (email, voice call, or snail mail) depending on the contact information available to UCLA Health. Eligible patients will also receive a text-message reminder after the initial invitation. Eight days after the first text reminder, patients eligible for our study will be randomized at a 1:6 ratio into a holdout control arm that does not receive a second text message vs. a text-message arm that receives a second text message.
Our secondary research question concerns which type of text reminder is more effective. To study this question, we will nest a 2x3 factorial design within the text-message arm. The first factor has two levels and is whether the text message focuses on patients' personal benefits or prosocial benefits. The second factor has three levels and is whether the text message highlights the early access patients have to the vaccine, whether it highlights that the vaccine offers the promise of a fresh start, or neither.
- In the Holdout arm: patients will not receive a second text message about COVID-vaccine.
- In the text-message arm, all participants will receive a text message that invites them to schedule their vaccination appointment and includes a link to the appointment website
- In the Self-benefit sub-arm, participants will be reminded that the vaccine helps protect themselves from COVID.
- In the Prosocial-benefit sub-arm, participants will be reminded that the vaccine helps protect their family, friends, and community from COVID.
- In the Early access + self-benefit sub-arm, participants will be reminded that they have early access to COVID-19 vaccine and should take the opportunity to protect themselves from COVID.
- In the Early access + prosocial-benefit sub-arm, participants will be reminded that they have early access to COVID-19 vaccine and should take the opportunity to protect their family, friends, community from COVID.
- In the Fresh start + self-benefit sub-arm, participants will be reminded that the vaccine offers the promise of a fresh start and they should take the opportunity to protect themselves from COVID and chart a new path forward.
- In the Early access + prosocial-benefit sub-arm, participants will be reminded that the vaccine offers the promise of a fresh start and they should take the opportunity to protect their family, friends, community from COVID and help our nation chart a new path forward.
Patients will enter our study on a rolling basis, as they become eligible to get the vaccine (and if they fit our inclusion criteria for receiving the second text message). Those in the text-message arm will receive the second text message on the workday on or closest to the 8th day following the first text message. Specifically, if t denotes the date of the first text message, then t+8 is the 8th day following the first text message.If t+8 is Saturday, the second text message will be sent on Friday; if t+8 is Sunday, the second text message will be sent on Monday. We will measure a) whether patients schedule a COVID-19 vaccination appointment for the first dose and b) whether and when patients get the first dose of COVID-19 vaccine.
The study will stop assigning patients to the early access + self-benefit sub-arm OR the early access + prosocial-benefit sub-arm when UCLA health opens appointments to everyone regardless of priority status related to age, health conditions or occupations. This will be done because at this point the concept of early access is likely no longer credible. At that point, we will randomize future patients eligible for our study at a 1:4 ratio into the holdout control arm and a text-message arm that receives a second text message. Within the text-message arm, we will nest a 2x2 factorial design, where the two factors will be a) whether the text message will focus on patients' personal benefits or prosocial benefits and b) whether or not the text message highlights that the vaccine offers the promise of a fresh start.
Analysis:
For the main analysis, we will run ordinary least squares regressions (OLS) with robust standard errors to predict the aforementioned outcome variables, except that we will use a Cox proportional hazards model with administrative censoring to predict time of obtaining the first COVID-19 vaccine. The significance level will be 0.05. Our primary hypothesis is that the text-message arm is significantly better than the holdout arm, so our primary analysis will compare the six text-message sub-arms altogether with the holdout group.
Our secondary analysis will investigate whether (1) the three sub-arms highlighting self-benefits, (2) the three sub-arms highlighting prosocial benefits, (3) the two sub-arms highlighting early access, and (4) the two sub-arms highlighting fresh start are better than the holdout arm.
Furthermore, we will test (1) the effect of highlighting prosocial benefits (vs. self-benefits), (2) the effect of highlighting early access, (3) the effect of highlighting the promise of a fresh start, (4) whether the combination of early access and prosocial benefits will outperform early access alone or prosocial benefits alone, and (5) whether the combination of fresh start and prosocial benefits will outperform fresh start alone or prosocial benefits alone.
Our regressions will include the following control variables:
- Participant age
- Indicators for participant race/ethnicity (Black non-Hispanic, Hispanic, Asian non-Hispanic, white non-Hispanic, other/mixed, unknown; white non-Hispanic omitted)
- Whether the patient's preferred language is Spanish (which affects the language of text)
- Indicators for participant gender (male, female, other/unknown)
- Social vulnerability index score
- COVID19 Risk Factors Model
- Indicators for the batches of patients (patients will become eligible and receive initial communications in batches)
As a robustness check, we will re-run the analysis as a logit regression (instead of an OLS regression) for binary outcome variables.
We will explore the following moderators:
- Whether the patient is female or male
- Whether the patient is Black, Caucasian, Hispanic, or other
- Whether the patient's preferred language is Spanish
- Whether the patient is 65+ (including 65) or below 65
- Patient's Social vulnerability index score
- Patient's COVID risk score
- Patient's population risk score
- Whether the patient is married (which is a proxy for whether they live together with family members)
- Whether or not the patient received a flu shot in either the 2019-2020 season or the 2020-2021 flu season prior to receiving our text message according to the patient's medical record
- The day of the week when the text message is sent to a patient. We will compare each day of the week.
- How strongly the participant's neighborhood is in favor of the Republican (vs. Democratic) Party if UCLA Health eventually agrees to provide de-identified address (e.g., zipcode)
- The arm that patients were assigned to for the first text message (see our pre-registration for the RCT related to the first text message at NCT04800965)
- Number of days between the date the first batch of patients received the initial invitation to get COVID vaccine at UCLA Health and the date a patient in question received the initial invitation
- The number of patients who have received the initial invitation to get COVID vaccine at UCLA Health before a patient in question received the initial invitation.
Plan for Early and Subsequent Analyses
To inform policy as soon as possible, we plan to first assess the effects of our interventions in the early phase of vaccination outreach at UCLA Health. For this purpose, we plan to first analyze the data from the start of this RCT to the end of February. Given that we are using a 6-day time window for our primary dependent variable, we will examine data from patients who are randomized to either the holdout or text-message arm in this RCT before or on Feb 23, 2021. For this population, we will test:
- whether the text-message arm is significantly better than the holdout arm;
- whether the three sub-arms highlighting self-benefits, the three sub-arms highlighting prosocial benefits, the two sub-arms highlighting early access, and the two sub-arms highlighting fresh start are better than the holdout arm.
- we will report the raw data for each sub-arm without conducting hypothesis testing across conditions that are not pre-registered in (1)-(4).
In our early analysis, we will include controls that are available to us (it is possible that we do not have all of the controls described above at the time of early report).
However, if by Feb 23, we do not reach 40K (which gives us 80% power to detect a 2pp difference between the holdout arm and the text message arm, assuming that holdout arm has a 50% baseline) for this RCT, we will only report estimated treatment effects and 95% confidence intervals but we will not perform any hypothesis testing.
After all UCLA patients have been invited (or if vaccine distribution plan changes and UCLA Health no longer sends out text messages to patients at some point), we will do the following additional analyses:
- If the additional data collected afterward exceeds 40K (which gives us 80% power to detect a 2pp difference between the holdout arm and the text message arm), then we will analyze the main effect of sending a text message (vs. holdout) and report the raw data for each sub-arm (to see if the patterns are qualitatively comparable with those in the early data).
- If we do not reach the sample size for the early analysis, then we will use all the data (including the early data and subsequent data) to analyze the aforementioned questions for the early data.
- We will use the full sample (including the early data and subsequent data) to analyze (1) the effect of highlighting prosocial benefits (vs. self-benefits), (2) the effect of highlighting early access, (3) the effect of highlighting the promise of a fresh start, (4) whether the combination of early access and prosocial benefits will outperform early access alone or prosocial benefits alone, and (5) whether the combination of fresh start and prosocial benefits will outperform fresh start alone or prosocial benefits alone, and (6) the aforementioned heterogeneous treatment effects.
Study design
- Primary purpose
- Health services research
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, care provider)
- Number of arms
- 7
| Arm | Type | Receives |
|---|---|---|
| Holdout Arm | No intervention | –In the Holdout arm: patients will not receive a second text message about COVID-vaccine. |
| Self-benefit sub-arm | Experimental | Behavioral: Self-benefitIn the Self-benefit sub-arm, participants will be reminded that the vaccine helps protect themselves from COVID. |
| Prosocial-benefit sub-arm | Experimental | Behavioral: Prosocial-benefitIn the Prosocial-benefit sub-arm, participants will be reminded that the vaccine helps protect their family, friends, and community from COVID. |
| Early-access and self-benefit sub-arm | Experimental | Behavioral: Self-benefit, Behavioral: Early accessIn the Early access + self-benefit sub-arm, participants will be reminded that they have early access to COVID-19 vaccine and should take the opportunity to protect themselves from COVID. |
| Early-access and prosocial-benefit sub-arm | Experimental | Behavioral: Prosocial-benefit, Behavioral: Early accessIn the Early access + prosocial-benefit sub-arm, participants will be reminded that they have early access to COVID-19 vaccine and should take the opportunity to protect their family, friends, community from COVID. |
| Fresh start and self-benefit sub-arm | Experimental | Behavioral: Self-benefit, Behavioral: Fresh startIn the Fresh start + self-benefit sub-arm, participants will be reminded that the vaccine offers the promise of a fresh start and they should take the opportunity to protect themselves from COVID and chart a new path forward. |
| Fresh start and prosocial-benefit sub-arm | Experimental | Behavioral: Prosocial-benefit, Behavioral: Fresh startIn the Early access + prosocial-benefit sub-arm, participants will be reminded that the vaccine offers the promise of a fresh start and they should take the opportunity to protect their family, friends, community from COVID and help our nation chart a new path forward. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- All patients who satisfy the following criteria will be eligible to be included in our study:
- They have a mobile phone number or SMS capable phone number in UCLA Health's database
- They are eligible for receiving the COVID-19 vaccine at UCLA Health
- They have not already scheduled an appointment the day before the scheduled time of the text message
- They are at or above 18 years old
Key exclusion criteria (0 listed)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Self-benefitParticipants will be reminded that the vaccine helps protect themselves from COVID. | Behavioural | Early-access and self-benefit sub-arm, Fresh start and self-benefit sub-arm, Self-benefit sub-arm |
| Prosocial-benefitParticipants will be reminded that the vaccine helps protect their family, friends, and community from COVID | Behavioural | Early-access and prosocial-benefit sub-arm, Fresh start and prosocial-benefit sub-arm, Prosocial-benefit sub-arm |
| Early accessParticipants will be reminded that they have early access to COVID-19 vaccine. | Behavioural | Early-access and prosocial-benefit sub-arm, Early-access and self-benefit sub-arm |
| Fresh startParticipants will be reminded that the vaccine offers the promise of a fresh start and chart a new path forward. | Behavioural | Fresh start and prosocial-benefit sub-arm, Fresh start and self-benefit sub-arm |
Primary outcome
First COVID-19 Vaccine Appointment Scheduled at UCLA Health
Time frame: 6 days
Whether patients schedule their vaccination appointment at UCLA Health within 6 days of receiving the second text message (including the day of text message). Specifically, if t=the date of the second text message (for the holdout arm, this refers to the date they would have received the text message had they not been assigned to the holdout arm), we will track vaccination appointments made by the end of t+5. While most people just make one appointment, a small percentage update their appointment time. We will have access to the latest few first-dose appointments people schedule by the time of data extraction.
4 secondary outcomes
First COVID-19 Vaccine obtained at UCLA Health
Time frame: 1 months from text message
Time of obtaining the first COVID-19 vaccine at UCLA Health
Time frame: 1 months from text message
First COVID-19 Vaccine obtained at UCLA Health or any organization reporting to CAIR
Time frame: 2 months from text message
Time of obtaining the first COVID-19 at UCLA Health or another location reporting to CAIR
Time frame: 2 months from text message
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 Sep 2022.
- Background: PubMed 29611455Brewer NT, Chapman GB, Rothman AJ, Leask J, Kempe A. Increasing Vaccination: Putting Psychological Science Into Action. Psychol Sci Public Interest. 2017 Dec;18(3):149-207. doi: 10.1177/1529100618760521.
- Background: PubMed 33315079Volpp KG, Loewenstein G, Buttenheim AM. Behaviorally Informed Strategies for a National COVID-19 Vaccine Promotion Program. JAMA. 2021 Jan 12;325(2):125-126. doi: 10.1001/jama.2020.24036. No abstract available.
- BackgroundDai, H., Milkman, K. L., & Riis, J. (2014). The fresh start effect: Temporal landmarks motivate aspirational behavior. Management Science, 60(10), 2563-2582.
- Individual participant dataSharing planned: No
Related trials for Covid19, Vaccines
Not yet recruitingPhase 1
A Safety, Reactogenicity and Immunogenicity Trial of RVX-sCPD9 Booster Intranasal COVID-19 Vaccine
COVID -19
RecruitingPhase 1
A Safety and Immunogenicity Trial of OCU500, ChAd36 Vector Encoding SARS-CoV-2 Spike Vaccine Via Intranasal and Inhalational Routes in Previously Vaccinated Adults
COVID-19
RecruitingPhase 2
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1283 in Participants ≥6 Months to <12 Years of Age
SARS-CoV-2
RecruitingPhase 4
Comparative Immunogenicity of Respiratory Virus Vaccines (CIRV2) Study
COVID -19, COVID - 19
RecruitingPhase 4
A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Formulations
SARS-CoV-2
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Self-benefit, Prosocial-benefit and Early access in people with Covid19, Vaccines, run by University of California, Los Angeles at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 0 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 13 Sep 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
First COVID-19 Vaccine Appointment Scheduled at UCLA Health (time frame: 6 days). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04801524, which also lists 3 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Sep 2022.